Patent ID: 7884122

Claim:
An oral dosage form comprising: (a) clonidine or a pharmaceutically acceptable salt thereof in an amount between about 0.001 wt % and 0.5 wt % of said oral dosage form; and (b) a pharmaceutically acceptable hydrophilic matrix comprising: (i) at least one hydroxypropyl methylcellulose ether in an amount between 20 wt % and 80 wt % of said oral dosage form; (ii) at least one of starch, lactose, or dextrose in an amount between 20 wt % and 80 wt % of said oral dosage form; and (iii) sodium lauryl sulfate in an amount of about 5 wt % of said oral dosage form; wherein after administration of said dosage form no more than once about every 24 hours to a subject having a steady state plasma concentration of clonidine, the clonidine plasma concentration peak-to-trough ratio is no greater than about 1.9.